European Leukemia Trial Registry
Trial: ALL Aplidin

less detail
Public Title Aplidin in relapsed/refractory ALL
Scientific Title A Phase II multicenter, open-label, clinical and pharmacokinetic study of Aplidin « (APLD) as a 1-hour weekly IV infusion, in patients with relapsed or refractory acute lymphoblastic leukemia (ALL)
Short Title ALL Aplidin
Id KN/ELN LN_GMALLE_2005_53
Trialgroup GMALL
Type of Trial multicentric
Phase Phase II
Disease Acute lymphoblastic leukemia(ALL) All subtypes
Stage of Disease relapsed/refractory
Inclusion Criteria
  • Written informed consent
  • Underlying disease: ALL in >=1st relapse or refractory
  • if 1st relapse: time from first treatment to relapse has to be <18 months
  • if >1st relapse: all patients are eligible
  • Site of relapse has to include bone marrow ▒ extramedullary relapse (e.g.CNS, testicular)
  • Previous line(s) of systemic chemotherapy should have been finished at least 3 weeks before patient registration
  • Prior radiotherapy is allowed.
  • Prior auto and/ or allo SCT is allowed.
  • In case of allo SCT, patient has to be off immunosuppressive agents
  • Recovery from any toxicity derived from previous treatments.
  • The presence of alopecia and NCI-CTC grade < 2 symptomatic peripheral neuropathy is allowed.
  • Age > 18 years.
  • Performance status (ECOG) < 2
  • Adequate renal and hepatic function
  • Creatinine clearance > 40 ml/min (Cockcroft and Gault formula)
  • Serum bilirubin ≤ 1.5 mg/dL and alkaline phosphatase ≤ 2.5 x ULN
  • AST, ALT < 2.5 x ULN
  • Albumin > 25 g/L
  • Left ventricular ejection fraction within normal limits.
Exclusion Criteria
  • Prior therapy with APLD
  • Wash-out periods since the end of the precedent therapy less than:
  • 6 weeks for nitroso-urea or high dose chemotherapy
  • 3 weeks for other chemotherapies or biological agents
  • 4 weeks for radiation or radionuclide therapy
  • 30 days for any investigational product
  • 2 weeks for immunosuppressive therapy after allo SCT
  • Pregnant or lactating women
  • Men and women of reproductive potential who are not using effective contraceptive methods (details see protocol)
  • History of another neoplastic disease. The exceptions are:
  • non-melanoma skin cancer
  • carcinoma in situ of any site
  • any other cancers curatively treated and no evidence of disease for at least 5 years.
  • Other relevant diseases or adverse clinical conditions:
  • Congestive heart failure or angina pectoris, myocardial infarction
  • Uncontrolled arterial hypertension
  • Uncontrolled cardiac supraventricular arrhythmias
  • Cardiac ventricular arrhythmia
  • History of significant neurological or psychiatric disorders
  • Active severe infection
  • Infection by HIV, HBV or HCV
  • Myopathy or any clinical situation that causes significant and persistent elevation of CK (>2.5 ULN in two different determinations performed with one week apart)
  • Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis)
  • Limitation of the patient’s ability to comply with the treatment or follow-up protocol.
  • Uncontrolled endocrine diseases (e.g. diabetes mellitus, hypothyroidism or hyperthyroidism)
  • Treatment with any investigational product in the 30 days period before inclusion in the study.
  • Known hypersensitivity to Aplidin, mannitol, cremophor EL, or ethanol
Age >= 18 years
Status Closed
Start of Recruitment 24.10.2005
Recruiting Countries Germany
Leader Junghan▀, Prof. Dr., Christian
Scientific Contact Junghan▀, Prof. Dr., Christian (Affliliation)
Contact Person

principal investigator
Junghan▀, Prof. Dr., Christian
Tel: +49 (0)381 494 7421
Fax: +49 (0)381 494 7422
Email: christian.junghanss@med.uni-rostock.de

Centre of Trial Universitńtsklinikum Rostock
Shortprotocol Shortprotocol
Sponsors Pharma Mar, S.A. (Main Sponsor)
Supporters Pharma Mar, S.A.
Interventions
  • Aplidin: 1-hour weekly IV infusion
Therapy During the Treatment Period, all patients are to attend study center visits on day 1,8,15 and 22 of every 28-day cycle. Patients will receive APLD only on day 1,8 and 15 of each cycle. Visit at day 22 must be performed in order to evaluate toxicity and adverse events. Treatment period will continue until disease progression, significant increase in ALL-related symptoms, unmanageable toxicity, withdrawal of patient’s consent or treatment delay>2 weeks (except in case of obvious patient’s clinical benefit).
created 06.07.2006 Anja Hellenbrecht
changed 05.11.2014 Alexandra Lucaciu
ę ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org